Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Personalis Inc PSNL

Technology Scientific & Technical Instruments
Personalis, Inc. is engaged in developing and marketing advanced cancer genomic tests and analytics. The Company’s advanced genomic sequencing and analytics support the development of personalized cancer vaccines and other next generation cancer immunotherapies. Its products include NeXT Personal, ImmunoI DNeXT, NeXT Personal Dx, NeXT Dx, whole exome sequencing (WES), and whole genome... see more

Recent & Breaking News (NDAQ:PSNL)

Personalis, Inc. to Present at Precision Medicine World Conference 2020

Business Wire January 22, 2020

Personalis, Inc. Announces the Launch of the NeXT Dx(TM) Test, a Comprehensive Genomic Cancer Profiling Test Enabling Advanced Composite Biomarkers for Cancer Treatment

Business Wire January 7, 2020

Personalis, Inc. to Present at ESMO Immuno-Oncology Congress 2019

Business Wire December 10, 2019

Personalis, Inc. to Present at NeoAg Summit US 2019

Business Wire November 21, 2019

Personalis to Present at Upcoming Investor Conferences

Business Wire November 19, 2019

Personalis, Inc. Announces Collaboration With Merck KGaA, Darmstadt, Germany, to Identify and Develop Novel Biomarkers for Cancer Therapies

Business Wire November 19, 2019

Personalis, Inc. to Present New Data at the AACR Tumor Immunology and Immunotherapy Conference

Business Wire November 17, 2019

Personalis Reports Third Quarter 2019 Financial Results

Business Wire November 13, 2019

Personalis, Inc. Expands Oncology Portfolio With the Launch of Cancer Whole Genome Sequencing Services

Business Wire November 12, 2019

Personalis, Inc. to Present New Data at the Society for Immunotherapy of Cancer (SITC) 34th Annual Meeting

Business Wire November 6, 2019

Personalis to Announce Third Quarter 2019 Financial Results on November 13, 2019

Business Wire October 30, 2019

Personalis, Inc. to Present at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2019

Business Wire October 24, 2019

Personalis, Inc. to Present at Advances in Immuno-Oncology Congress USA 2019

Business Wire October 8, 2019

Personalis Receives New Order from the VA's Million Veteran Program - Total Awarded to Date Now $145M

Business Wire September 26, 2019

Personalis Appoints Karin Eastham to Its Board of Directors

Business Wire September 12, 2019

Personalis, Inc. Enters Into Research Agreement With Invectys to Provide Comprehensive Tumor Immunogenomics Profiling for Clinical Trial

Business Wire September 9, 2019

Personalis to Participate in the 17th Annual Morgan Stanley Global Healthcare Conference

Business Wire August 26, 2019

Personalis Reports Second Quarter 2019 Financial Results

Business Wire August 13, 2019

Personalis, Inc. to Provide Comprehensive Tumor Immunogenomic Profiling to the New Mexico Cancer Care Alliance for Clinical Study

Business Wire August 7, 2019

Personalis, Inc. Announces Integration of New ImmunoID NeXT Platform(TM) Features in Latest Expansion of Immuno-Oncology Biomarker Discovery Applications

Business Wire August 1, 2019